News

US subsidiary of Swiss-based InSphero AG initiates direct product shipments, progresses towards full-scale US bioproduction capabilities.

New delivery method boosts efficiency of CRISPR genome-editing system.

Agreement further supports Teva’s novel biologics development program.

Microreactor replaces animal testing.

A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.

Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.

Combined scientific, financial and human resources will support robust gene therapy pipeline.

Abbott and Alere Inc. have announced a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership.

This study is the first to examine the effects of BPA and BPS on brain cells and genes that control the growth and function of organs involved in reproduction.

Alliance will give access to the renowned expertise of Domainex in protein expression, biochemical assays and hit identification.